All Articles

An Interview with Donna Moore Wilson, RN, MSN, CBCN, of the Virginia Cancer Patient Navigator Network

On September 26, 2019, the FDA approved daratumumab (Darzalex; Janssen) in combination with bortezomib, thalidomide, and dexamethasone for the treatment of newly diagnosed patients with multiple myeloma who are eligible for autologous stem-cell transplant (ASCT). The FDA granted this application priority review.

Oncology navigation encompasses countless topics in the world of oncology.

The authors evaluate the effects of yoga on physiological and psychosocial side effects of chemotherapy and biotherapy.

Ovarian cancers with BRCA mutations are less immunogenic than other DNA repair–deficient tumors.

Patients with ovarian cancer can respond to immunotherapy, but rationally designed synergistic combinations will be necessary to enhance upfront efficacy and to sustain durability, said Daniel J. Powell, Jr, PhD, Scientific Director of Immunotherapy, Division of Gynecologic Oncology, University of Pennsylvania, Philadelphia, at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium.

A paradigm shift away from “one-size-fits-all” treatment in cancer has fueled the movement toward precision medicine, an approach to cancer treatment that ensures delivery of the right intervention to the right patient at the right time.

Adolescent and young adult (AYA) patients aged 15 to 39 years are significantly underrepresented in cancer clinical trials.

When patients’ sexual functioning is compromised as a result of cancer treatment, so is their quality of life. Here’s what navigators can do to incorporate sexual preservation into survivorship care.